Loss of ZNF677 Expression Is an Independent Predictor for Distant Metastasis in Middle Eastern Papillary Thyroid Carcinoma Patients

• Published in: International journal of molecular sciences Vol. 22; no. 15; p. 7833
• Main Authors: Siraj, Abdul K., Poyil, Pratheesh Kumar, Parvathareddy, Sandeep Kumar, Alobaisi, Khadija, Ahmed, Saeeda O., Al-Sobhi, Saif S., Al-Dayel, Fouad, Al-Kuraya, Khawla S.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-08-2021; MDPI
• Subjects: AKT protein; Apoptosis; Cancer therapies; Carcinogenesis; Carcinogens; Cell growth; Confidence intervals; distant metastasis; DNA methylation; Epigenetics; Lung cancer; Medical prognosis; Metastases; Metastasis; Papillary thyroid carcinoma; Patients; Phosphorylation; Protein expression; Proteins; Statistical analysis; Thyroid cancer; tumor suppressor; Tumor suppressor genes; Tumors; zinc finger protein 677
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22157833

Thyroid cancer incidence has increased in recent decades. Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Approximately 30% of PTC patients develop recurrence or distant metastasis and tend to have poor prognosis. Therefore, the identification of targetable biomarkers in this subset of patients is of great importance. Accumulating evidence indicates that zinc finger protein 677 (ZNF677), which belongs to the zinc finger protein family, is an important effector during the progression of multiple malignancies. However, its role in Middle Eastern PTC patients has not been fully illustrated. Here, we uncovered the molecular mechanism and the clinical impact of ZNF677 expression in a large cohort of more than 1200 Middle Eastern PTC and 15 metastatic tissues. We demonstrated that ZNF677 is frequently downregulated in primary PTC (13.6%, 168/1235) and showed that complete loss of expression of ZNF677 is significantly associated with aggressive clinico-pathological markers such as extrathyroidal extension (p = 0.0008) and distant metastases (p < 0.0001). We also found a significantly higher incidence of ZNF677 loss in primary tumors with distant metastases (33.3%; p < 0.0001) as well as in distant metastatic tissues (46.7%; p = 0.0002) compared to the overall cohort (13.6%). More importantly, PTC with loss of ZNF677 expression showed significantly lower metastasis-free survival (p = 0.0090). Interestingly, on multivariate logistic regression analysis, ZNF677 loss was an independent predictor of distant metastasis in PTC (Odds ratio = 2.60, 95% Confidence interval = 1.20–5.62, p = 0.0155). In addition, we found a significant association between ZNF677 loss and phospho-AKT expression (p < 0.0001). Our functional molecular results suggest that ZNF677 acts as a tumor suppressor, mediating its effect by inhibiting AKT phosphorylation. Taken together, our results highlight the pivotal role played by ZNF677 during carcinogenesis and metastasis formation in Middle Eastern PTC patients.